DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division

DataMEDS implemented cost-control measures including reductions in corporate management positions to focus spend on commercializing the ChemoFx diagnostic assay, initially for gynecologic cancers only. ChemoFx was recently included for the first time in a Humana Medicaid coverage policy, and the company is preparing a marketing relaunch with discussions underway with hospital systems, HMOs, GPOs and cancer centers. The update follows the September 11, 2026 acquisition of Helomics, whose Predictive Oncology division controls a repository of over 70,000 de-identified tumor samples across more than 130 tumor types that the company plans to monetize via AI research collaborations.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.